1

HEARING DAY ONE

2 Canadian Light Source, University of Saskatchewan: 3 Application for an amendment to its Particle 4 Accelerator Operating Licence 5 THE CHAIRPERSON: I would, 6 therefore, like to begin the hearing today by 7 calling for an oral presentation by Canadian Light 8 Source as outlined in the CMD documents 02-H25.1 9 and 02-H25.1A. I will turn it over to Mr. 10 BENMERROUCHE. 11 Good morning, sir. 12 13 02-H25.1 / 02-H25.1A 14 Oral presentation by Canadian Light Source 15 MR. BENMERROUCHE: Madam President 16 and Chair, Members of the Commission, CNSC staff, 17 ladies and gentlemen, good morning. 18 My name is Mohamed BENMERROUCHE. 19 I am the Manager of Health, Safety and Environment 20 of the Canadian Light Source Inc. CLSI for short. 21 Accompanying me today is Bill Thomlinson, 2.2 Executive Director of CLSI, who is on my left 23 here; Mark de Jong, Director of Operations, who is 24 on my left further down; and Les Dallin, Manager 25 of Accelerator Operations at CLSI, who is behind

StenoTran

1 Tony Whitworth, Vice-President of Finance and us. 2 Resources of the University of Saskatchewan, U. of 3 S., could not be here with us today, but will be 4 available via conference call to answer any 5 questions the Commission Members may have. 6 The first slide shows a recent 7 picture of the Canadian Light Source facility. 8 The purpose of this presentation is to provide 9 Members of the Commission with a summary of the 10 information that was submitted to the CNSC staff 11 in support of an amendment to the operating 12 licence to authorize Phase III beam commissioning 13 of the CLS. 14 Phase I beam commissioning, which 15 included the linac, was approved by the Commission 16 on May 28, 2001, and the required tests and 17 radiological characterization were completed on 18 March 3, 2002. 19 Phase II beam commissioning was 20 approved on December 11, 2001, and the amendment 21 for the booster commissioning was approved on June 2.2 7, 2002. The initial tests and radiological 23 characterization for Phase II commissioning were 24 completed on September 26, 2002. 25

Today's application is concerned

StenoTran

1 with the third phase of commissioning the CLS, 2 which includes the storage ring and beam lines. 3 My presentation is organized as 4 follows. First I would like to start with an 5 introduction. I will briefly describe the various 6 phases required for commissioning the CLS 7 facility. A final report on Phase I commissioning 8 will be discussed, followed by a preliminary 9 report on Phase II commissioning. I will then 10 discuss Phase III application and finally present 11 the summary and conclusion. 12 The CLS facility includes high 13 energy, low power in the few watts range, electron 14 accelerator and synchrotron light beam lines in 15 the infrared to hard x-rays energy range from .02 16 electron volts to 100 Kilo electron volts. The 17 accelerator is considered a class 1B electron 18 accelerator. 19 The next slide describes the 20 various components of the CLS facility. The 21 proposed commissioning of the CLS will proceed 2.2 under three phases which will be described in the 23 next few slides. 24 Phases I and II have been

24 Phases I and II have been
 25 completed. Phase III is expected to start

StenoTran

February 2003, and we are here today seeking the
 Commission's approval to proceed to Phase III of
 the CLS commissioning.

The electron accelerator system 4 5 includes three major components: 300 million 6 electron volts linear accelerator, a 2.9 billion 7 electron volts booster synchrotron, and a 2.9 8 billion electron volts storage ring. The 220 KEV 9 electrons generated by the gun are bunched and 10 accelerated to about 250 MeV in the linear 11 accelerator, linac. They are then transported 12 from the linac to the booster via the linac to the 13 booster transfer line for injection into the 14 booster.

15 The electrons are then accelerated 16 in the booster to a final energy of 2.9 GeV, 17 before they are extracted from the booster and 18 transported into the BTS or booster-to-storage 19 transfer line for injection into the storage ring. 20 This process continues once per 21 second for up to 120 booster cycles, about two 2.2 minutes, as it is required to reach an average 23 circulating current of 500 milliamps in the 24 storage ring. However, numerous effects result in 25 the loss of electrons from the storage ring over a

StenoTran

1 period of several hours to tens of hours. The storage ring is refuelled when 2 3 the average circulating circuit has decayed to 4 half its nominal value of 500 milliamps. 5 The CLS facility will be used for 6 its synchrotron light which is emitted in the 7 tangential direction of the electrons orbit in the 8 storage ring. The synchrotron light is very 9 intense and ranges from infrared to hard x-rays, 10 typically in the range of .01 electron volts to 11 100 kilo electron volts. 12 The light is directed toward an 13 experimental station using synchrotron light beam 14 lines. The synchrotron light is a powerful tool 15 for basic and applied studies in biology, 16 chemistry, medicine, physics and environmental, as well as applications to technology such as x-ray 17 18 lithography micro-machines, material 19 characterization and trace element analysis. 20 This picture here represents the 21 dipole magnets that bend the electron beam upwards 2.2 from the sub-basement toward the linac to the 23 booster tunnel located at the basement level. The 24 beam dump shown here is the end point of Phase I. 25 The bending magnet is the starting point of

StenoTran

1 Phase II.

This picture depicts part of the linac-to-booster transfer line located in the basement level. The beam dump, where the beam was directed during Stage I or Phase II commissioning is identified.

7 This shows the injection area into 8 the booster ring. The injection septum in blue 9 and the kicker magnet in silver are identified. 10 The direction of the electron beam is from right 11 to left.

Here we show part of the booster ring inside the booster tunnel. The blue structures are the dipole magnets which keep the electron beam in orbit around the booster ring. The green structures are the quadrupole magnets, which focus the electron beam.

The booster extractor septum is shown in blue here. The beam dump, shown here, is the end point of Phase II. The beam was not taken beyond this point during Phase II commissioning.

A section of the storage ring is shown here with the support pedestals and girders and a few magnets. The red and green magnets are the sextupoles and quadrupoles respectively.

StenoTran

1 The storage ring magnets are shown 2 here wrapped and awaiting installation. The 3 installation of all magnets is expected to be 4 completed by April 2003. 5 Here is a wide angle view of the 6 storage ring bulk shielding and its ratchet wall 7 structure. A typical opening from which the 8 synchrotron beam lines will be emerging is 9 indicated. 10 The proposed beam commissioning of 11 the CLS will proceed under three distinct phases. 12 The commissioning of the CLS will be carried out 13 under the same operating licence PA10L-02.02/2006. 14 Currently the operating licence limits the 15 operation of the accelerator to Phases I and II 16 only, as indicated under licence condition C2. A 17 Commission approval is required prior to 18 proceeding with subsequent commissioning phases. 19 This will require the amendment of the operating 20 licence and submission of supporting 21 documentations. 2.2 Phase I is the recommissioning of 23 the existing linac accelerator and part of the 24 linac to the booster transfer line, LTB, up to the 25 beam dump BST0004-01. The linac and this part of

StenoTran

1 the LTB are located in the sub-basement of the 2 facility. 3 Phase II involves the 4 commissioning of the booster ring, including the 5 remainder of the LTB transfer line and part of the 6 booster-to-storage transfer line or BTS up to beam 7 dump BST1400-01. The LTB brings the electron beam 8 from the sub-basement level to the main level, where the booster ring and the BTS are located. 9 10 Phase III involves the 11 commissioning of the storage ring, including the 12 remainder of the BTS transfer line. This phase 13 will also include the eight synchrotron beam 14 lines. It is expected that this phase will be 15 ready for beam commissioning in February 2003. 16 At the completion of Phase III 17 commissioning, a request will be submitted to 18 amend the licence to authorize routine operations. 19 The CLS facility is projected to begin normal 20 operations in January 2004. 21 The drawing shown here depicts the 2.2 start and end point of the three commissioning 23 phases. Phase I is shown in red; Phase II is 24 shown in green; Phase III is shown in blue. 25 Phase I commissioning included the

StenoTran

1 recommissioning of the linac and commissioning of 2 the linac-to-booster transfer line up to the beam 3 dump BTS0004-01. It began on June 29, 2001 and continued until March 3, 2002. Phase I beam 4 5 commissioning for radiological characterization 6 was conducted in two parts. Part 1 dealt with the 7 radiation measurement taken at the electron energy 8 of 180 million electron volts or MeV and ran from 9 August 28, 2001 until September 23, 2001. 10 Part 2 involved measurements of 11 the nominal operating energy of 250 MeV and ran 12 from January 17, 2002 until March 3, 2002. The 13 commissioning proceeded as planned with all the 14 necessary precautions in place. A final report 15 was submitted to the CNSC in August 2002. 16 A summary of the radiological 17 measurements are illustrated in the next few 18 slides. 19 Before we do that, here I 20 illustrate the various axis zones within the main 21 floor level of the CLS facility. Similar zone 2.2 designation is used on other levels of the 23 facility. The green shaded area belongs to the 24 free access zone and the yellow shaded area

25 belongs to the restricted access zone.

StenoTran

1 The reception area within the 2 lobby level, as well as outside the facility, are 3 considered the public access zone. In addition, 4 measurements have been carried out in the occupied 5 areas within each zone. 6 The radiation levels within a 7 restricted area during normal beam operating 8 conditions are indicated in red here. For 9 comparison, the background levels, when the beam 10 is off, are shown in blue. 11 TLDs were used for the measurement 12 of the total accumulated radiation. This chart 13 displays the accumulated gamma dose during the 14 indicated exposure period at various locations 15 within the free and restricted access zones. 16 The minimal detectable dose for 17 this kind of TLD is .1 milliSieverts. The larger 18 peak is measured in the location within the 19 restricted access zone, not accessible to 20 personnel when the beam is on. The dose was 21 measured under normal beam operating conditions, 2.2 as well as missteering scenarios. 23 The same as the previous chart but 24 for the neutron monitoring. 25 Illustrated here is the gamma

StenoTran

1 radiation body dose exposure distribution of the 2 commissioning team during the third quarter from 3 July 15 to October 14 and fourth quarter, October 15 to January 14 of 2001 and the first guarter, 4 5 January 15 to April 14, 2002. 6 Phase I beam commissioning 7 occurred in the third quarter of 2001 and the 8 first quarter of 2002. Only one person received a 9 dose of 0.2 milliSieverts. The rest of the 10 commissioning team received less than the minimal 11 detectable dose of .1 milliSieverts. 12 Similar to the previous slides but 13 for the CLS personnel not involved in the beam commissioning activities. 14 15 The result of the measurements 16 shown in the green bars are compared with the 17 shielding model predictions in the blue bars. The 18 theoretical calculations tend to overestimate the 19 measured radiation levels up to a factor of three 20 difference. However, the trend of the data is 21 reasonably well reproduced. 2.2 Phase II commissioning included 23 commissioning of the LTB transfer line not covered 24 under Phase I, the booster ring and part of the

25 booster-to-storage transfer line. The

StenoTran

commissioning began on June 2002 and continued until September 2002. The commissioning proceeded as planned with all the necessary precautions in place.

5 Radiological measurements were 6 carried out in the occupied area within the public 7 access, free access and restricted access zones. 8 The radiological data is being analyzed and some 9 preliminary results have been submitted to CNSC 10 staff. Some recently analyzed data can be shown 11 at the conclusion of this presentation if the CNSC 12 is interested.

13The CLSI has provided the required14information in support of Phase III commissioning15approval application.

16 The analysis of radiation hazards 17 for Phase III operations are described in the CLS 18 safety report and Photon Beamlines Safety 19 Guidelines. The design criteria, as well as the 20 radiation shielding calculations, have been 21 reviewed by CNSC staff. The bulk shielding for 2.2 the storage unit was completed in April 2001. 23 The conventional technical 24 construction report pertinent to Phase III

25

StenoTran

commissioning has been incorporated in the CLS

1 safety report. The verification and validation of 2 the storage ring access control interlock system, 3 which is an integral part of the personnel safety 4 system, was completed in September 2002. The full 5 report was submitted to the CNSC. 6 The Phase III commissioning plan 7 describes the principal components of the BTS, 8 storage ring, and synchrotron beam lines 9 components and the actions required to safely 10 commission and meet the requirements as the final 11 stage of the CLS commissioning. 12 The composition of the Phase III 13 commissioning team has been provided to the CNSC 14 staff, including their qualifications and 15 experience in accelerator operations. The CLSI 16 staff has many years experience in designing, 17 installing and commissioning electron 18 accelerators. 19 The CLS human factor workscope 20 specifies the human factor analysis, design and 21 assessment activities that are to be undertaken in 2.2 support of the design, commissioning and operation 23 of the CLS facility. Recent submissions included 24 accelerator operator qualifications and training, 25 and operator task description and validation plan.

StenoTran

1 The installation of the storage 2 components and services should be completed ring 3 by April 2003. The installation of photon beam 4 lines and services should be completed by 5 September 2003. 6 The U. of S. has established 7 Canadian Light Source Inc. to lead the 8 construction product and operate the facility. An 9 agreement entitled "University of Saskatchewan and 10 Canadian Light Source Inc. License Agreement" has 11 been established between the U. of S. and CLSI to 12 ensure the continued expansion, maintenance and 13 operation of the facility in a manner to ensure it 14 is a state-of-the-art synchrotron light facility. 15 The agreement includes articles on CLSI duties and 16 obligations, the U. of S. licence of the facility, 17 appointments, health safety and environment, 18 reporting and monitoring, facility enhancement and 19 maintenance, communications and marketing, 20 indemnity and insurance, term and termination. 21 The CLS Inc. hold the CNSC licence 2.2 to construct and operate the facility. The CLSI 23 has primary responsibility for all health, safety 24 and environmental programs at the CLS facility 25 under the direction of the CLSI Executive

StenoTran

1 Director. The CLSI Executive Director is the 2 signing authority on the CNSC licensees. The CLSI 3 Health Safety and Environment Manger is authorized 4 to act as the contact person on all technical 5 issues associated with the CLSI licenses 6 pertaining to the CNSC and other regulatory 7 authorities.

8 The Preliminary Decommissioning 9 Plan or PDP was revised taking into account the 10 CNSC review comments. Detailed decommissioning 11 cost estimates have been developed to give a 12 reasonable justification for the total 13 The U. of S. has been decommissioning cost. 14 involved in the preparation of the decommissioning 15 plan and cost estimates. The U. of S. has 16 accepted the decommissioning final end-state 17 objectives. The building and its associated 18 conventional services will not be dismantled and 19 will be available for other uses by the U.of S. 20 CLSI will establish a restricted 21 decommissioning fund to ensure that adequate 2.2 resources are available to complete the identified 23 decommissioning activities. The restricted fund 24 will be funded from the operational budget of the 25 CLSI and reviewed periodically for adequacy and

StenoTran

changes in circumstances. Prior to establishment of the entire fund required, a financial guarantee from the U. of S. will be provided for the full amount of the decommissioning costs. The financial guarantee, if required, will be in the form of a letter of credit.

7 The CLS keeps the public fully 8 informed as the project develops. The CLSI has 9 been conducting frequent presentations and tours 10 of the facility. Individuals are often given a 11 handout or brochure, shown a promotional video, 12 and/or a slide presentation. Background 13 information includes the facility overview, some 14 scientific research applications, and some items 15 of general interest such as introduction of HSE 16 programs. An HSE poster is displayed prominently 17 at the CLS facility.

18 A variety of communication 19 vehicles have been used, such as news conferences, 20 new releases, media interviews, videos, brochures, 21 newspaper supplements, advertisements, tours, 2.2 public lectures and community open houses. 23 Audiences include general public, media, Canada's 24 science community, federal and provincial 25 politicians, federal granting councils that fund

StenoTran

1 the CLS, prospective corporate partners, users, 2 customers and high school students and so on. 3 An outreach coordinator has been participating in various workshops, arranging 4 5 public tours, preparing educational and 6 promotional material. Recently, commissioning of 7 the booster was covered by local media. 8 In summary, Phase I commissioning 9 of the linac LTB was satisfactory. Radiological 10 measurements and their various beam loss scenarios 11 were carried out and show that the radiation 12 levels are below the design levels under normal 13 operating conditions. 14 Phase II commissioning, which 15 includes the booster ring, was completed in 16 September 2002. Comprehensive radiological 17 measurements have been carried out and we are in 18 the process of analyzing the data. 19 In regard to the Phase III 20 application, we believe that we have met all the 21 requirements for Phase III commissioning. We, 2.2 therefore, respectfully request the Commission to 23 approve an amendment to the operating licence 24 authorizing CLSI to proceed to Phase III 25 commissioning of the CLS.

StenoTran

1 Thank you for your attention, and 2 we look forward to answering any questions the 3 Commission Members might have. 4 THE CHAIRPERSON: Thank you very 5 much. 6 7 02-H25 / 02-H25.A 8 Oral presentation by CNSC staff 9 THE CHAIRPERSON: With the 10 concurrence of the Commission Members, I am going 11 to turn to CNSC staff before I open the floor for 12 questions. On that basis, I would like to turn to 13 Mr. Barclay Howden, who is Director of Research 14 Facilities Division, to give the staff 15 presentation. 16 These are outlined in CMD 17 documents 02-H25 and 02-H25.A. Mr. Howden. 18 MR. HOWDEN: Madam Chair, Members 19 of the Commission, for the record, my name is 20 Barclay Howden, Director of the Research 21 Facilities Division. Mrs. Maloney is not well 2.2 today; thus, she is unable to attend the hearing. 23 With me today are Mr. Ramzi Jammal, Director of the Class 2 Facilities and Dosimetry Services 24 25 Licensing Division, Dr. Jacinthe Plante, Project

StenoTran

1 Officer in the same division, and Mr. Peter 2 Fundarek, Project Officer in the Wastes and 3 Geosciences Division. Canadian Light Source Incorporated 4 5 has completed Phase II commissioning of the CLS 6 facility and has applied to be allowed to proceed 7 to Phase III commissioning. My presentation this morning will 8 9 cover the key points of CMDs 02-H25 and 02-H25.A, 10 which recommend the amendment of the particle 11 accelerator operating licence to allow Canadian 12 Light Source Incorporated to perform Phase III 13 commissioning of the Canadian Light Source 14 particle accelerator facility at the University of 15 Saskatchewan. 16 To outline our presentation, I 17 will start with a description of the commissioning 18 phases for the facility, followed by a brief 19 update on outstanding issues from the last public 20 hearing on November 15, 2001 and the status of 21 other programs; CNSC staff's position on the 2.2 application; the proposed hold point on the 23 licence; and, finally, CNSC staff conclusions and 24 recommendations.

CLS Incorporated has proposed to

StenoTran

25

commission the facility in three phases. Phase I
included the recommissioning of the linear
accelerator or linac and part of the linac-tobooster transfer line. CLS Incorporated has
completed Phase I commissioning and submitted its
report. This report has been accepted by CNSC
staff.

8 Phase II is now completed. Ιt 9 included commissioning the remainder of the linac-10 to-booster transfer line, the booster and the 11 booster-to-storage ring transfer line up to the 12 beam dump BST1400-01, the boosters and electron 13 synchrotron accelerator that accelerates electrons 14 to 2.9 giga electron volts. In order to lift a 15 hold point during this phase, a licence amendment 16 was authorized by a designated officer in June 17 2002.

18 The draft preliminary Phase II 19 commissioning report was delivered to CNSC staff 20 this week. A review of the report has just 21 started.

Phase III includes commissioning of the remainder of the booster-to-storage ring transfer line, the storage ring and the synchrotron radiation beam lines. The storage

StenoTran

ring is a synchrotron in which the electrons will keep circulating for a few hours. A licence amendment is necessary before proceeding with each phase. And after Phase III commissioning, CLS Incorporated will have to request another amendment of their licence to authorize routine operation.

8 After the previous public hearing 9 on the CLS application in November 2001, there 10 remained several items that needed clarification 11 These were: and follow-up by CLS Incorporated. 12 The relationship between CLS Incorporated and the 13 University of Saskatchewan, preliminary 14 decommissioning plan, decommissioning cost 15 estimates, financial guarantee and, finally, human 16 factors.

17 Regarding the first issue, a new 18 contract has replaced the previous one, clarifying 19 the relationship between CLS Incorporated and the 20 University of Saskatchewan. This contract 21 specifies that CLS Incorporated has the full 2.2 authority and responsibility for holding CNSC 23 licences and to operate the facility while meeting 24 legal requirements. CNSC staff finds this 25 contract, as it relates to the protection of

StenoTran

1 health, safety and the environment, acceptable. 2 Regarding the second issue, a 3 revised preliminary decommissioning plan was 4 submitted to the CNSC and it has been accepted by 5 CNSC staff. Regarding the decommissioning cost 6 estimates, CNSC staff has determined that further 7 clarification is required before CNSC staff can 8 conclude that the cost estimate for 9 decommissioning is adequate. It is anticipated 10 that this issue will be closed in January 2003. 11 When that is done, work on an appropriate 12 financial guarantee can be completed. 13 With regard to a financial 14 guarantee, CLS Incorporated has proposed a 15 financial guarantee consisting of a separate fund 16 to be built up over a period of time, 17 supplemented, as required, by a letter of credit 18 from the University of Saskatchewan. CNSC staff 19 acknowledges this commitment. However, time will 20 be required to work out the details after the cost 21 estimates are finalized. Therefore, CNSC staff 2.2 has recommended a licence condition to address 23 this issue. 24 Regarding human factors, CLS 25

StenoTran

Incorporated is working on the proposed changes at

2.2

1 the CLS facility. Some of the changes are 2 physical, such as improving signage throughout the 3 facility, while others are process related, such 4 as making procedures more user friendly. CNSC 5 staff finds the progress on this issue acceptable. 6 In previous applications, a number 7 of programs were reviewed and judged to meet 8 requirements. CNSC staff revisited the following 9 four programs: Quality assurance, environmental 10 protection, emergency preparedness and response, 11 and conventional health and safety, and determined 12 that they continue to meet requirements. 13 Additionally, CNSC staff has 14 visited the facility four times in the past two 15 The most recent visit, an inspection in years. 16 September 2002, confirmed that the radiation 17 safety measures and controls needed for further 18 commissioning are in place. 19 For the licence amendment 20 application, the CNSC staff review included the 21 report on Phase I commissioning, including 2.2 information on the radiation surveys taken, the 23 commissioning plan for Phase III, radiation safety 24 during Phase III commissioning, including the 25 lock-up procedure for Phase III, the licence

StenoTran

agreement between the University of Saskatchewan
and CLS Incorporated, the qualification of CLS
Incorporated staff for Phase III of commissioning,
and preliminary decommissioning plan. Staff found
these items acceptable.
Phase III includes the

7 commissioning of the beam lines located outside 8 the accelerator shielding wall. Presently CLS 9 Incorporated has submitted only partial 10 information about the beam lines. The risk from 11 synchrotron radiation is considered to be much 12 lower than the radiation produced from the 13 acceleration of the electrons. In addition, the 14 design of the beam lines incorporates safety 15 features that will further reduce the radiological 16 risk to the workers.

17 Nevertheless, if the Commission 18 allows the project to go to Phase III, CNSC staff 19 proposes a hold point that prevents CLS 20 Incorporated from commissioning of the beam lines 21 without a licence amendment. Additionally, 2.2 because the risk from synchrotron radiation is 23 much lower than accelerator area radiation and 24 because the radiation protection strategy, namely 25 shielding, personnel exclusion interlocks and

StenoTran

radiation monitoring that has been successfully employed in the previous two phases of commissioning, will be used for the beam lines too,CNSC staff proposes that the amendment to lift the hold point be considered by a designated officer.

7 CNSC staff, therefore, concludes 8 that the application to amend the licence to 9 permit Phase III commissioning of the Canadian 10 Light Source facility is acceptable; CLS 11 Incorporated is qualified to carry on Phase III 12 commissioning; and CLS Incorporated will make 13 adequate provision for the protection of the 14 environment, the health and safety of persons and 15 the maintenance of national security.

16 CNSC staff recommends that the 17 Commission accept the CNSC staff's assessment that 18 an environmental assessment is not required; amend 19 the particle accelerator operating licence issued 20 to CLS Incorporated to allow Phase III of 21 commissioning; delegate to a designated officer 2.2 the exercise of the authority for releasing the 23 hold point to allow CLS Incorporated to commission 24 the beam lines; include a condition requiring a 25 financial guarantee in the CLS licence.

StenoTran

1 Please note that for consistency 2 with recent licence conditions on financial 3 guarantees, the licence conditions should read 4 slightly different than what is on the slide. Ιt 5 should read: 6 "The licensee shall provide 7 no later than December 31, 2003 a financial guarantee 8 9 for decommissioning 10 acceptable to the Commission 11 or a person authorized by the 12 Commission." 13 The words the "licenced facility in a form and value" have been removed for 14 15 consistency with other licence conditions. 16 Finally, delegate to a designated 17 officer the exercise of the authority to determine 18 the acceptability of a financial guarantee. 19 That concludes my presentation. 20 Staff is available to respond to questions. Thank 21 you. 2.2 THE CHAIRPERSON: Thank you, Mr. 23 Howden. 24 The floor is now open for 25 questions. I will start on my right. Dr. Barnes,

StenoTran

1 do you have any questions? 2 MEMBER BARNES: I would like to 3 address the issue of the financial guarantee, if I 4 may, because there seems to be an inconsistency at 5 least in the documents that we have here. T refer 6 specifically to staff CMD 02-H25, section 2.1. 7 That is at the base of page 2, a sentence in the 8 middle of that last paragraph states as follows: 9 "According to this contract, 10 CLSI is responsible for the 11 security, the insurance, the 12 decommissioning and the 13 financial quarantee." 14 Yet, elsewhere in the documents --15 I am not sure I have that at my fingertips -- I 16 think it was from the university that the 17 university has essentially the responsibility 18 under the agreement for providing the financial 19 Is it the university or CLSI? quarantee. 20 THE CHAIRPERSON: Since you quoted 21 a CNSC document, Dr. Barnes, I would suggest that 2.2 the staff should start, and then go to the 23 university. 24 MR. HOWDEN: With regard to the 25 financial guarantee, in the contractual agreement

StenoTran

between the University of Saskatchewan and CLSI Incorporated, there is a stipulation that CLSI Inc. will develop the separate decommissioning fund out of its operating funds over a period of time.

6 In the preliminary decommissioning 7 plan, which is where the financial guarantee is 8 actually proposed, that separate fund is 9 identified to be established, but then there is a 10 statement that, in the interim, as the fund is 11 built up, that the University of Saskatchewan 12 would then provide the letter of credit to cover the amount required for full decommissioning until 13 14 the fund gets up to that particular point. 15 MEMBER BARNES: If I then come 16 back to the wording of your licence condition, it 17 is the licensee who shall provide the financial 18 quarantee for decommissioning, which is CLSI, 19 which essentially doesn't have the financial 20 resources to provide that guarantee? 21 MR. HOWDEN: At the moment, that 2.2 is the case.

23 MEMBER BARNES: How can you ask 24 the licensee in this licence condition to do 25 something which is quite clear it has the

StenoTran

1 inability to do so?

2 MR. HOWDEN: It would be similar 3 to a case where another licensee did not have the 4 financial resources but went to the bank to get a 5 letter of credit to be supplied to them. 6 In this case, CLSI would get a 7 letter of credit from the University of 8 Saskatchewan to cover that fund. 9 MEMBER BARNES: So you expect by 10 December 31 for CLSI to have that letter from the 11 university giving you that assurance? 12 MR. HOWDEN: At this moment in time, we expect by December 31, 2003 that we would 13 14 have an acceptable financial guarantee. We 15 haven't determined whether the letter of credit 16 from the University of Saskatchewan would be 17 acceptable yet. 18 MEMBER BARNES: We have two weeks 19 to go and it is Christmas in there. You are 20 trying to put a condition in here -- okay, thank 21 you. 2.2 Would the THE CHAIRPERSON: 23 applicant like to add anything to that, to the 24 guestion from Dr. Barnes? 25 Mr. Whitworth.

StenoTran

1 MR. WHITWORTH: Dr. Whitworth. 2 Thank you very much. Thank you for the 3 arrangements made for me to participate today. 4 In answer to Dr. Barnes' question, 5 the university has been making arrangements to 6 provide a letter of credit to the project to cover 7 off the requirements for the financial component 8 of the decommissioning plan. It was deemed that 9 if you like, the credit worthiness of the 10 university at this point was greater than CLSI, so 11 that it is easier for the university to secure 12 that letter of credit. 13 I hope that answers the concerns 14 that Dr. Barnes has raised. 15 THE CHAIRPERSON: Thank you. Any 16 further questions, Dr. Barnes, at this time. 17 MEMBER BARNES: No. 18 THE CHAIRPERSON: Dr. McDill. 19 MEMBER McDILL: Thank you. I just 20 have a few questions. We received a package of 21 basically cover pages from documents that were 2.2 received previously. Can you tell me if the rest 23 of the document contains the remaining signatures? 24 Each of these has only one signature. I have a 25 number of them here. One is dated 2002/09/10. Ιt

StenoTran

1 is 8.12.90.1, revision A, CLS Commissioning Phase 2 III, and it is signed by E.L. Helene, but the 3 remaining signatures are blank. 4 MR. BENMERROUCHE: We submitted 5 numerous documents in support of Phase III 6 commissioning. Most of the documents have been 7 signed by all reviewers as being approved, except 8 for a few documents. One of them is the beam 9 lines. Still some of the comments are being 10 incorporated. 11 MEMBER McDILL: I have five 12 documents in front of me with only one signature. 13 Does that sound about right to you. 14 MR. BENMERROUCHE: I see probably 15 there is only three that have not been fully 16 signed. But the remainder of the documents have 17 been signed, reviewed and approved and sent to the 18 CNSC staff. 19 The documents related to the beam 20 lines have been signed by the authors, but are 21 still under review currently. One of the 2.2 questions that we have, we need to -- the 23 decommissioning document has been fully signed and 24 approved by the university and we submitted that 25 to the CNSC staff.

StenoTran

1 MEMBER McDILL: That is the 2 preliminary decommissioning plan? 3 MR. BENMERROUCHE: And also the 4 cost estimate. There is another document 5 describing the cost. 6 MEMBER McDILL: How about the 7 safety report? 8 MR. BENMERROUCHE: The safety 9 report is still under review. But the safety 10 report and the document relating to the beam 11 lines, two of them are pertaining to the review, 12 and some of the comments are being incorporated in 13 those three documents. 14 So only three documents. The rest 15 of them have been fully approved. 16 MEMBER McDILL: Thank you. I have 17 one other question. What is the approximate size 18 of the CLSI? You have a number of drawings 19 showing the site but no scale. 20 MR. BENMERROUCHE: The main 21 building is square and it is roughly 83 by 84 2.2 The old building, it is a bit tricky. meters. Ιt 23 is what, an L shape. 24 But the new building is the bigger 25 structure and it is 83 by 84 meters.

StenoTran

1 MEMBER McDILL: Approximately how 2 much green space in rough numbers surrounds the 3 building? I understand it is a compass so it is a 4 bit tricky. 5 MR. BENMERROUCHE: I will just 6 give you some numbers. There are a few buildings 7 not far away from the CLSI building within, let's 8 say, 40 meters. On the north side is a large 9 green field and there is a road that separates the 10 university and also the Elevation Centre and there 11 is also the waste management across. 12 Did that answer your question? 13 MEMBER McDILL: Thank you. That 14 is fine. 15 THE CHAIRPERSON: Mr. Graham. 16 MEMBER GRAHAM: Thank you. I have 17 a couple of questions with regard to the slide 18 presentation. The first one is on page 6, the LTB 19 tunnel that you presented this morning. 20 That LTB tunnel and the beam dump, 21 was that in operation at the time? 2.2 MR. BENMERROUCHE: Yes. 23 MEMBER GRAHAM: Just for 24 clarification for safety purposes, in the slide it 25 shows some nylon rope tying up some things there

StenoTran

1 that don't look very professional compared to the 2 chain falls that would be used to lift. So would 3 you like to comment on that, if you notice right 4 on the far left-hand side near the magnets. 5 MR. BENMERROUCHE: Mark de Jonq, 6 Operations Director, is going to answer this 7 question. 8 MR. de JONG: When I take a look 9 at that photo, that photo was taken during final 10 assembly of that. The indication of that is the 11 far left-hand side shows the vacuum chamber 12 connections and it is obviously wide open. So 13 there was certainly no beam that could have gone 14 through there. That photo was taken during 15 construction, I can tell. 16 MEMBER GRAHAM: Nylon rope is not 17 there now, I presume? 18 MR. de JONG: No. 19 MEMBER GRAHAM: Another guestion I 20 have is with regard to your slide 17, normal 21 conditions, it is radiological conditions in a 2.2 restricted area. What is good and what is bad 23 here? Sometimes arrows show good, bad, 24 indifferent. What I am wondering is, and I quess 25 that would be to the CNSC staff, are any of these

StenoTran

1 graphs, to the extent that should cause concern, 2 any of the graphs on page 17? 3 MR. HOWDEN: From a staff 4 perspective, these are all acceptable. 5 MEMBER GRAHAM: Even the second 6 one, where it is T1 IM, which goes up to 1.8, that 7 is acceptable, is it? 8 MR. HOWDEN: Yes, it is. That is 9 a restricted access area during operation. 10 MEMBER GRAHAM: If we could go to 11 page 20, commissioning team radiation exposure 12 distribution. I presume that is number of 13 persons, that is nine persons in total had 14 exposure and one of them reached a dose of over 15 0.2 milliSieverts. I doubt if it is unacceptable, 16 but is that anything to be alarmed about or not? 17 Would you comment on that? 18 No, the dose limits MR. HOWDEN: 19 for people are 50 milliSieverts in any year and 20 20 milliSieverts averaged over five years and this is 21 .2 milliSieverts. 2.2 Are all of the MEMBER GRAHAM: 23 people that are involved in this operation, those 24 nine and within the operation there, are they all 25 in the national registry for exposure? I believe

StenoTran

1 there is a national registry, isn't there, for 2 people working in the industry, and are these 3 people recorded in the national registry? 4 MR. HOWDEN: Yes, they are all in 5 the national dose registry. 6 MEMBER GRAHAM: I have just one 7 other question, Madam Chair, on page 21. Is there 8 anything in that slide that would be cause for 9 concern? As a layperson, sometimes it is hard to 10 understand high, low, arrow and so on, but your 11 comment on that also? 12 MR. HOWDEN: We have just received 13 this information so we haven't had a chance to 14 take a good look at it. I would like to maybe 15 suggest that Canadian Light Source comment upon 16 it. 17 MR. BENMERROUCHE: I assume you 18 are referring to page 21? 19 That is correct. MEMBER GRAHAM: 20 The number of persons, I presume that between 70 21 and 80, and above 80 means may not be 80 different 2.2 persons, but there could be one person with eight 23 different times in there or ten, I presume? 24 MR. BENMERROUCHE: For these 25 slides, the number of persons actually for the .4

StenoTran

1 milliSieverts there is only one person. For the 2 yellow there is also one person who received .2 3 milliSieverts. Also, these are monitored on a 4 regular basis and also they are in the national 5 registry. 6 Again, these levels are below the 7 limit, the CNSC limits, and well below our design 8 criteria also for CLSI. 9 MEMBER GRAHAM: If I may just have 10 one other question again as a layperson. 11 I realize it is acceptable, but is 12 this blue more or less for the norm? I mean, 13 people working in the industry would receive doses 14 of.01 milliSievert. That would be for the norm 15 and that would be even walking around, a visitor 16 would contract that much or is that something that should the scale be way down as time goes on, down 17 18 to 10 or 12 or even less than that? 19 MR. HOWDEN: I am going to ask 20 Ramzi Jammal to respond to you. 21 MR. JAMMAL: Yes, the public level 2.2 occupational dose is 1 milliSievert at .4. That 23 is below the 1 milliSievert limit. 24 But as your question is based on 25 the national dose registry, people in that

StenoTran

1 industry, these levels actually are within the 2 national average and, if anything, it is just a 3 little bit below. 4 However, since we received this 5 information today, we have asked CLS to actually 6 give us the information why it is .4, even though 7 it is below the limit. They are providing the 8 information to us, actually. 9 THE CHAIRPERSON: Perhaps I could 10 just clarify. Slide 20 is the number of people as 11 part of the commissioning team, which is a total 12 of nine persons. Is that correct? 13 MR. BENMERROUCHE: Yes, it is 14 correct. 15 THE CHAIRPERSON: Slide 21 is the 16 non-commissioning personnel, and that means a 17 total of, depending on the quarter, anything from 18 mid seventies, to low eighties were personnel that 19 were in the facility in the non-commissioning. Ιs 2.0 that correct? 21 MR. BENMERROUCHE: Correct. 2.2 THE CHAIRPERSON: Then in terms of 23 each of those brackets, the red line means one 24 person, the yellow line means one person? 25

MR. BENMERROUCHE:

Yes.

1 THE CHAIRPERSON: So in the third 2 quarter of 2001, you had one dose of greater than .2 milliSieverts and one between .1 and less than 3 4 .2, is that correct, in terms of interpretation 5 for the yellow dose for quarter 3? I am just 6 clarifying with Mr. Graham the question because 7 Mr. Graham had raised the issue: Is this actual number of persons, and the answer is yes, it is. 8 9 Is that correct? 10 Yes, It is the MR. BENMERROUCHE: 11 number of persons. 12 I just want to add one more point. 13 Unfortunately, the greater sign is not correctly 14 put in there. The red ones are doses greater than 15 .2 milliSieverts. It does not include . 2. The 16 yellow ones include the doses between .1, anything 17 above .1 and less or equal to .2. 18 I also want to add something. Ιf 19 you measure the dose around the CLS facility, just 2.0 from natural background, you will get roughly 21 between .3 to .4 milliSieverts a guarter for any 2.2 person in the public just sitting there. 23 So typically levels which are .2 24 milliSieverts are below level. It is just like 25 background exposure.

StenoTran

1 THE CHAIRPERSON: Mr. Graham, did 2 you have a guestion of clarification? 3 MEMBER GRAHAM: Just as 4 clarification. There was one person, though, with 5 the highest dose in that quarter three that was 6 equal to .0.4. Is that right? 7 MR. BENMERROUCHE: Yes, one 8 person. 9 MEMBER GRAHAM: So that red is 10 more than .2, but it was .4. That is what you are 11 saying? 12 Yes, the red MR. BENMERROUCHE: 13 ones are the doses greater than .2 milliSieverts. 14 And greater than .2 milliSieverts includes only 15 one person, which is .4. 16 MEMBER GRAHAM: CNSC staff are 17 going to review that because you just got that 18 information today. Is that my understanding? 19 MR. JAMMAL: Yes, that is very 2.0 We just asked the CLS this morning on this true. 21 issue, even though it is acceptable, we would like 2.2 to have further investigation from CLS as to what 23 happened. 24 THE CHAIRPERSON: Just finally for 25 the record, could the CNSC staff state the

StenoTran

1 guideline that you use for these facilities in 2 terms of doses? 3 MR. JAMMAL: Sorry, can you 4 elaborate on your guestion a little bit more. The 5 quidelines to determine the doses to the workers 6 or the calculation that was used to determine the 7 doses? 8 THE CHAIRPERSON: The doses for 9 the workers, what would be acceptable and should 10 be not exceeded in this facility? 11 MR. JAMMAL: Again, we have the 12 national dose registry levels that are being 13 published based on the workers' occupation and the 14 range that is expected of people in their 15 occupation, administrative and medical groups and 16 so on and so forth. These are the national 17 quidelines that we are using to compare against. 18 THE CHAIRPERSON: And what are 19 they? 20 They vary widely, MR. JAMMAL: 21 I am sorry if I am not giving you the actually. 2.2 right answer. Probably I didn't understand the 23 question properly. But they vary, depending on 24 the occupation and the classification of the 25 worker.

StenoTran

1 The classification of nuclear 2 energy workers, in the guidelines there is a 3 maximum limit. For the general public again it is 4 1 milliSievert and we are monitoring against this. 5 The guideline is literally the exposure based on 6 occupation to the work and the ranges of the 7 worker in that group of people. 8 THE CHAIRPERSON: I quess what I 9 am trying to get for the record is this. You have 10 a commissioning team and you have some doses here, 11 and my understanding is that this is still well 12 below the limit that would be acceptable in this 13 facility. Then you have a non-commissioning 14 personnel with exposure. For the record, and I 15 think Mr. Graham referred to this too, you have 16 these levels given. How do they compare to what 17 would be the guidelines that can't be exceeded for 18 this facility? Is it 1 per cent, 10 per cent or 19 is it 150 per cent? What exactly are we looking 20 at here, and that is for the record, and the 21 people that read these transcripts. 2.2 MR. JAMMAL: For the record of 23 these people, .4 milliSievert is roughly 60 per 24 cent below the 1 milliSievert limit to the general 25 public in that occupation.

StenoTran

1 Ms MacLachlan. THE CHAIRPERSON: 2 MEMBER MacLACHLAN: In making the 3 CNSC presentation this morning, you referred to 4 documentation that the CNSC had just received last 5 week and you had not had an opportunity to review 6 it. 7 I wanted you to clarify what that 8 was and what the implication was for this hearing 9 I understand from the comments that the today. 10 information represented in one or two of the 11 slides in the presentation made earlier by the 12 Canadian Light Source, that information wasn't 13 received. Was there further information that is 14 pertinent to this hearing today received by CNSC? 15 MR. HOWDEN: In terms of 16 information that was received, the slides from CLS 17 that were used today, we received approximately at 18 the same time you did, approximately a week ago 19 because of the supplementary deadline, which I 20 think were based on the preliminary Phase II 21 results or to a certain extent. I am not 100 per 2.2 cent sure of that. 23 But we also received on Monday, 24 the preliminary Phase II commissioning report, 25 preliminary. It didn't have all the information

StenoTran

1 in place.

2 What we have done is for this 3 hearing we reviewed the Phase I report, which we 4 accepted. We looked at the Phase III 5 commissioning plan, but the important thing that 6 we did was we went to the facility on September 7 28th of this year, while Phase II was still 8 ongoing, to look at the safety measures that they 9 were going to have in place for Phase III. So 10 even though they were continuing commissioning 11 beyond that point to make sure that the machine 12 was running I guess as they would want the machine 13 to run, we went in and looked at those safety 14 measures and those, specifically, were is the 15 shielding in place and within specifications, are 16 the personnel exclusion interlocks in place, and 17 we verified they were, and is the radiation 18 monitoring systems that are there to assist them 19 and to warn them if there is a problem, are they 20 in place.

21 At that time, yes, they were. We 22 verified it. So that gave us confidence to come 23 to the Commission to recommend it based on Phase I 24 report and our inspection during Phase II of the 25 measures being put in place to protect the workers

44

StenoTran

1 for Phase III.

2 So with regard to the Phase II 3 commissioning report, we will definitely be 4 looking at it to see if there is anything that has 5 come out that was unexpected and we would follow 6 up on that through our routine compliance 7 activities with the licensee. 8 MEMBER MacLACHLAN: Thank you very 9 much. 10 I have another question for CLS 11 and the university. This is with respect to the 12 fund that you are wanting to establish for 13 decommissioning. 14 You say that it is a separate 15 decommissioning fund, but I would like to receive 16 assurances that this would be a fund that would 17 not be merged in any way with general revenues or 18 general accounts of the university and that there 19 would be terms attached almost as though the money 20 were in trust for very specified purposes that are 21 tied to the licence. 2.2 I will direct MR. BENMERROUCHE: 23 this question to Mark de Jong, and then after that 24 the university, Tony. 25 MR. de JONG: It is our intent to

StenoTran

establish that as the detailed legal mechanics to be worked out for the financial. But it will be effectively a separate trust fund exclusively for decommissioning.

1

2

3

4

5 The arrangements that we are 6 making with the university for the letter of 7 credit are to basically cover any difference 8 between what is in the fund at any one time and 9 what is required for actually decommissioning. 10 Yes, Dr. THE CHAIRPERSON: 11 Whitworth, are you interested in speaking? 12 I will just MR. WHITWORTH: 13 reinforce what Dr. De Jong has said. The plan is 14 to establish a trust fund, a restricted trust 15 fund, into which on an annual basis monies from 16 CLS will be deposited and gradually built up to 17 meet the letter of credit commitment that the 18 university will have made. 19 Dr. Giroux. THE CHAIRPERSON:

20 MEMBER GIROUX: I will start by 21 following up on this and asking Dr. Whitworth: 22 You made a strong statement before and I think you 23 have reinforced it today or repeated it today that 24 the University of Saskatchewan is backing the 25 financial guarantee.

StenoTran

1 But you don't have actual final 2 numbers as to the cost of decommissioning yet. So 3 I was wondering what is the form of your 4 agreement? I don't need numbers, but does it 5 state a maximum or does it state just whatever 6 will be required, whatever it costs. 7 MR. WHITWORTH: Today we have 8 worked on the best assumptions and are planning that the letter of credit meet the requirements of 9 10 the CNSC, whatever that might be. We have had 11 estimates within a certain range. The 12 university's commitment is to meet what is 13 required. 14 MEMBER GIROUX: Thank you. That 15 answers my question. 16 I have a follow-up on the previous 17 discussion raised by Ms MacLachlan about the staff 18 making a recommendation with incomplete results 19 I understand, and I heard your answer, from II. 20 that you are going to look at that. I am assuming 21 that you are confident that nothing will come up 2.2 in the report that might jeopardize your 23 recommendation today of going to Phase III, 24 because you have a strong recommendation, and you 25 have to be confident that there is nothing faulty

StenoTran

1 in the Phase II operations in commissioning, and 2 the results that might require redesigning or 3 retrofit or something. 4 Could you make a clear statement 5 on that. 6 Yes, we are confident MR. HOWDEN: 7 Part of it is based on the past results on that. 8 that we have seen from Phase I, plus from our 9 latest inspection. During those times, there were 10 11 radiation measurements done to confirm that the 12 predictions were actually much higher than what 13 was expected. Based on that, plus the programs 14 that they have in place, specifically quality 15 assurance, the emergency response, health and 16 safety, which we have deemed acceptable, provide 17 another level of assurance that they are going to 18 continue to operate safely into the future. 19 So we do have that level of 20 confidence. If something does come up, which can 21 always happen, we would have to take a look at the 2.2 situation and, if necessary, take regulatory 23 action. We have certain tools at our disposal 24 such as requests through Section 12.2 of the 25 general Regs or orders under the Nuclear Safety

StenoTran

1 and Control Act.

2 But, yes, based on what we have 3 seen and what we are seeing, we are confident that 4 Phase III can be performed safely. 5 MEMBER GIROUX: Thank you. 6 Turning now to CLS, I have a few technical 7 questions. 8 On page 15 of the first document 9 we received, the one with text, you talk about 10 possible missteering scenarios. Can you give me 11 one or two examples of what could happen, what 12 could go wrong in steering? 13 MR. BENMERROUCHE: One of the 14 components of the accelerator is you have steering 15 coils that you steer the beam left or right or up 16 or down. Very, very mild steering. We are not 17 talking about bending the beam. 18 During the commissioning, we take 19 measurements during the normal operation. You 20 take the beam to whatever location is required. 21 Then we also took measurements, what if the 2.2 missteering is done to the limits of the steering 23 coils and see what is the consequences of that. 24 We have numerous steering coils along the 25 accelerator just to steer the beam, and we also

StenoTran

1 use some diagnostics to see where the beam is. 2 They call them sometimes popups or transitional 3 radiation monitors. We look at all those various 4 5 scenarios and say, what are the consequences; what would be the rendition under those consequences, 6 7 and then what to do in case nothing happened. 8 So far for the Phase I, I will 9 summarize the Phase I, because the whole 10 accelerator structure is in the sub-basement and 11 the shielding for all the accelerator system under 12 the sub-basement is overly shielded, we barely see 13 anything unusual. All the levels that we measured 14 everywhere -- we have taken comprehensive 15 measurements -- they were within fluctuation 16 levels. 17 The reason we can say that is 18 because we also did measurements before the 19 machine was running, well before, to see what were 20 the radiation levels in the facility and then we 21 compared against. So even under missteering 2.2 conditions we didn't anything find anything 23 substantial in the free access or the restricted

access zones.So all the radiation is well
contained within the accelerator closures. That

StenoTran

1 is for Phase I.

2 For Phase II it is a little bit 3 different. We have to bring the beam up into the 4 main hall and then the whole accelerator is into 5 the main floor, and all the shielding is new. So 6 under those conditions, we had to be very careful 7 and do all the measurements that we can do, both inside and outside, because the whole main ring 8 9 can also has some consequences for the outside 10 building.

11 We have taken measurements over 12 500 points all around the facility, in the free 13 access zone, in the public access zone and the 14 restricted access zone. Furthermore, we also use 15 passive area monitoring. We have those TLDs that 16 we put around the facility inside and outside and 17 in all occupied locations, including offices, for 18 example, and we exchange those on a guarterly 19 basis.

20 So far, in the free access area, 21 the radiation levels are within the background 22 fluctuations. We did notice if you bring the beam 23 into certain locations, for example, if you take 24 the beam and you dump it into a specific location, 25 you will expect that the radiation level

StenoTran

1 downstream from that beam dump will be higher 2 because you are dumping the beam in a certain 3 location. So certain peaks that we saw are well 4 understood and under control, and you can always 5 shield those with local shielding. 6 But to summarize, the bulk 7 shielding, as far as I can tell, it is 8 satisfactory and it is adequate for the booster. 9 So the levels are quite reasonable. I am very 10 confident that there is not going to be any big 11 The only issue is to maybe provide some issue. 12 local shielding in certain areas, for example, 13 some of the openings in the shielding and all 14 that. But those are under control, so we know 15 where they are. 16 MEMBER GIROUX: Thank you. A 17 further question. I will be referring to slide 18 22. That is where you give us the calculation 19 versus the experimental measurements. I was 20 surprised to see on the right of the graph you 21 have the theoretical measurements and the 2.2 radiation, I guess, two or three times as high as 23 the actual one. I was wondering what was the 24 source of that? Is that difficult to predict or 25 is it over conservative design?

StenoTran

1 If you look at MR. BENMERROUCHE: 2 a model, in order to make the model more usable, 3 you need to know what the source of radiation is. 4 And then from that source, you see what is between 5 the source and the location where you want to 6 measure that radiation. 7 Under the accelerator, the source 8 of radiation is not well defined. It could be 9 lost anywhere. That is why in the previous graph 10 you see almost a flat distribution, because when 11 the beam is lost you don't see a specific peak 12 like when we have a beam dump. You will see it 13 more or less level off. 14 To make contact with the monitor 15 predictions you need to see what the source is. 16 You can either have a line source or a point 17 source, and it becomes really hard because when 18 you look at the accelerator structure, there are 19 so many things in between. There is, for example, 20 the magnet shielding. You can see beam pipe; you 21 can see conduits; you can see cables; you can see 2.2 It is quite complicated. concrete. 23 What we have done is we have just 24 taken a few points where we think we can make 25 comparisons and, based on that assumption, we say

StenoTran

what is the prediction. We have done the same thing for Phase II and the model predictions are the same thing. Well, they overpredict the values. In general, the model predictions tend to overestimate the measured values. MR. THOMLINSON: A way to think

8 about modelling in this situation is you have to 9 take a worst case assumption. In fact, the way 10 you do that the losses, as has been stated, are 11 generally fairly distributed. But for the 12 modelling, you essentially can take a point source 13 for the radiation and, therefore, you always will 14 overestimate, and that is the appropriate 15 procedure. Then you shield against that 16 overestimation.

17MEMBER GIROUX:So there is some18intentional conservativeness in your modelling?19MR. THOMLINSON:Absolutely.20very conservative modelling is always the approach21in this type of shielding.

THE CHAIRPERSON: Perhaps I could just start round 2. Dr. Barnes do you have any further questions?

25

MEMBER BARNES: I have to return

StenoTran

1 to where I left off the last time with the 2 financial guarantees. 3 To staff, I may have misheard you 4 I think you said that by this coming then. 5 January, next month, you would have some agreement 6 on the decommissioning costs. Is that what I 7 heard? 8 MR. HOWDEN: Yes, we had a meeting 9 with CLS Incorporated a couple of weeks ago to 10 discuss the costs and to discuss the issues that 11 we needed clarification on. From that meeting, we 12 felt that CLS Incorporated understood our concerns 13 through the discussions and that they would be 14 able to resubmit the cost estimates to address the 15 points of clarification that we required. 16 MEMBER BARNES: If I understand 17 it, you have reached a fairly firm agreement or 18 understanding between the two sides here on the 19 level of financial guarantee. If that is the 20 case, why does the licence condition have the date 21 December 31, 2003? In other words, why do you 2.2 need another year in order to have that specific 23 guarantee received by you? 24 MR. HOWDEN: We are requesting 25 that time period because we still think, for the

StenoTran

1 financial guarantee, it will require much more 2 discussion with CLS Incorporated. The financial 3 quarantee proposed by CLS Incorporated is sort of 4 two-pronged, where they are going to build up the 5 decommissioning fund, which, in their agreement 6 with the University of Saskatchewan does stipulate 7 that that fund has to be acceptable to the CNSC. 8 That was another question that was raised earlier. 9 Then you go to the letter of 10 credit from the University of Saskatchewan. 11 Traditionally, for financial guarantees, we have 12 not been accepting financial guarantees directly 13 from other entities other than banks or 14 government. So we wanted to explore that further. 15 Really, the issue is: Is the 16 amount that is being proposed low enough such that 17 the risk is low enough that we can accept a letter 18 of credit from the University of Saskatchewan as 19 opposed to from a bank. Mrs. Maloney has directed 20 our staff to review this potential position and 21 make recommendations to her, the reason being 2.2 because it could impact other licensees who have 23 relatively low financial guarantees required on 24 whether they have to go to a bank or whether they 25 can get a guarantee from an institution such as a

StenoTran

1 university.

2 I believe it is going to take time 3 to work out those issues and also to examine our 4 own position on financial quarantees. 5 MEMBER BARNES: Can I come to the 6 second issue, and that is how the fund is actually 7 built up I quess just to paint two scenarios, one 8 scenario is that there is a low user community and 9 the other is that there is a full user community. 10 In other words, part of the revenues for the 11 operation of the light source certainly comes from 12 the partners, as I understand it, and also there 13 will be a set of user fees that will generate part 14 of the income. 15 The fund, presumably, is going to 16 be accumulated by some transfer of monies either 17 from the partners, the partner contributions, or 18 from the user fees. 19 I am trying to find out whether 20 this is built up annually by sort of a guaranteed 21 amount that would come in irrespective of the user 2.2 fees, i.e. therefore, all of the responsibility 23 falls back to the partners or to the university, 24 or whether it is essentially built up as an

amount, assuming there is a surplus.

StenoTran

1 Is there a guarantee that this 2 fund will be built up in a systematic way 3 irrespective of the total operating revenues 4 received by the Canadian Light Source? 5 MR. BENMERROUCHE: T will direct 6 this question to Mark de Jong. 7 MR. de JONG: The discussions that 8 we have had on building up the fund is the intent 9 that if the facility has an anticipated life span 10 of approximately 20 years to build that full fund 11 up over that period of time, we are talking 12 somewhere between \$250,000 and \$300,000 a year. 13 That is based on what we have on that current 14 estimate for the decommissioning. 15 That will be coming right off the 16 top; that will be part of our basic commitment 17 going in each year regardless of what number of 18 users we have. That is certainly what we are 19 planning on when we were working on our budget. 20 The funding partners for 21 operations, we have certainly been informing them 2.2 that the contributions to this decommissioning 23 fund will be part of what we will be using with 24 their ongoing contributions. It will not be 25 dependent upon the user fees.

StenoTran

1 MEMBER BARNES: So I understand 2 that that is accepted. You have not only informed 3 them, but they accept that as part of the 4 arrangements? 5 MR. de JONG: One of the funding 6 partners is the University of Saskatchewan and 7 they have certainly accepted that. Their 8 commitment is over \$1 million a year. We will 9 have that amount of money from someone that will 10 permit us to use it in that fashion. 11 MEMBER BARNES: To the staff, I 12 assume this is also part of the financial 13 guarantee issue, this issue of a guarantee to be 14 able to build up the decommissioning fund 15 appropriately? 16 MR. HOWDEN: That is correct. 17 THE CHAIRPERSON: Dr. Giroux. 18 MEMBER GIROUX: I have a further 19 question about the hold point that you are 20 discussing in the document. Before you send the 21 beam lines outside the shielded area, my question 2.2 Will decommissioning include hitting actual is: 23 targets with the beam line or will it be only with 24 beam dumps outside the storage ring? 25 If I understand MR. BENMERROUCHE:

StenoTran

1 correctly, your question is whether or not we are 2 going to be using any beam dumps inside the 3 storage ring? 4 MEMBER GIROUX: Beam dumps or 5 If you are commissioning, you actual targets. 6 have to get close to operating conditions. My 7 question is: How close do you get to operating 8 conditions? Does commissioning of the beam lines 9 outside the storage ring include hitting actual 10 targets as you will be doing other operations?

11MR. BENMERROUCHE:Bill Thomlinson12will take the question.

13 MR. THOMLINSON: Commissioning of 14 the Phase III includes, first of all, working with 15 the shield wall completely intact, operating the 16 storage ring itself at various operating 17 conditions so that we are sure of its stable 18 operation also in sort of non-normal operations. 19 Once we have achieved that point, 20 then it is because there are no radiation ports 21 open; everything is contained inside the shield 2.2 wall. There are some beam lines being constructed 23 which are diagnostic beam lines. They will be 24 looking at the beam at that point.

25 Then further to your question,

StenoTran

1 which is a very good point, in order to apply for 2 routine operations, the actual beam lines, at 3 least those which are present at the time -- and 4 they are all very similar in terms of safety 5 operations -- it will be necessary to bring the 6 photons, the light, the radiation, not the 7 electrons -- electrons are contained within the 8 storage ring always -- to bring the light out, 9 down the various beam lines, which are in 10 existence, under controlled radiological surveys, 11 various types of conditions and fault conditions 12 and so forth, under the control of a commissioning 13 team prior to any utilization by experimental 14 But we will have to, in fact, emulate the users. 15 real world. We will have to put the optics in 16 place. You will get scattering from the various 17 Optics are just like mirrors and so optics. 18 forth, mirrors and apertures and so forth to 19 define the beam for the end user. We will have to 20 bring the beam into the last part of the beam line 21 where the actual experiments take place. 2.2 Of course, all of that is based 23

23 upon prior measurements and validation of the 24 safety systems and exclusion and so forth. But it 25 will have to be to that point, otherwise we could

StenoTran

1 not ask for routine operations.

2 MEMBER GIROUX: Thank vou. Τs 3 staff comfortable with that scenario? MR. HOWDEN: Yes, we are. 4 The 5 main thing that we will be focusing on is that it 6 is the synchrotron radiation coming out and not 7 any other radiation coming out. 8 MEMBER GIROUX: A further 9 question. You mention on page 4 of staff's 10 document that there is some radiation or 11 contamination resulting from the electron beam 12 impacting on components. What is the typical 13 duration of the resulting contamination? Is that 14 measured in seconds, minutes, hours or whatever? 15 MR. HOWDEN: With regard to the 16 impact of the beam, it is not contamination. Τt 17 is actually activation of the components and the 18 time to decay away could be from seconds to hours, 19 depending on the materials, depending on what 20 parts are being activated. 21 MEMBER GIROUX: There is no real 2.2 problem of accumulation in there if it decays that 23 rapidly? 24 There will be MR. HOWDEN:

accumulation over time. From a standpoint of

25

StenoTran

1 safety, local shielding is used to protect the 2 workers for that. Also, when it comes to decommissioning time, how much activated the 3 4 components or the shielding is will determine 5 exactly how much of the facility has to be taken 6 apart and it depends on the activation at that 7 But it will accumulate, yes. time. 8 MEMBER GIROUX: Thank you. My 9 final guestion is: What is the rate of 10 utilization of the beam which is expected of the 11 storage ring? What per cent of the time in terms 12 of hours per day will the storage ring be 13 operating? 14 MR. BENMERROUCHE: T want to make 15 sure I understand the question before I answer it. 16 Are you talking about how long the 17 beam in the storage ring --18 MEMBER GIROUX: The beam in the 19 storage ring. I think you mentioned that you have 20 to replenish it after four hours? 21 MR. BENMERROUCHE: Between four 2.2 hours to ten of hours, yes. 23 MEMBER GIROUX: But is your plan 24 always to have a beam active within the storage 25 rinq?

StenoTran

1 MR. BENMERROUCHE: Yes. I want to 2 summarize how the whole process works. There is 3 an injection system that we need to inject 4 electrons in the storage ring. Then once the 5 electrons are in the storage ring, they circulate 6 for hours. At one point, you are going to start 7 losing electrons and you have to replenish or 8 refill the storage ring. The refill can range 9 between four hours to ten, 12 hours. It depends 10 on many, many factors. 11 But as far as the injector system, 12 that is what the whole commissioning is about, 13 Phase I, Phase II, it is only going to be running 14 up to two minutes every four to ten of hours. 15 Then after that, the whole system will shutdown 16 and there will be no radiation. Then any time you 17 need to refill the ring, you just start the whole 18 injector system again, which is the linac, the 19 booster and the BTS. That is why the measures 20 that you measured so far, we have to take into 21 account the duty factor of the machine. 2.2 Mark de Jong would like to add 23 something. 24 MR. de JONG: I just wanted to 25 add. I think the other half of your question is

StenoTran

1 the usage throughout the year.

2 It is our intent that once we get 3 into routine operation, that in the first year we 4 will probably operate the storage ring 5 approximately 2,000 hours a year, but that as a 6 mature facility over three or four years, we will 7 basically have beam in the storage ring 8 approximately 5,000 hours a year. That is pretty 9 typical of the production of a lot of these other 10 facilities. 11 That entails basically 24 hours a 12 day, seven days a week for extended periods of 13 times, followed by one month to two month 14 shutdowns to allow any major revisions on some of 15 the beam lines. 16 MEMBER GIROUX: Thank you. That 17 is very informative. I was anticipating the 18 operating licence hearing, but I was curious. 19 Thank you. 20 THE CHAIRPERSON: My questions are 21 what I would call clean up questions in terms of 2.2 this is an amendment to the licence, but I just 23 want to check. These are questions to staff. 24 There are a number of areas under 25 the licence that haven't been discussed today, and

StenoTran

1 I just want to make sure that you are still 2 satisfied with the compliance of the licensee in 3 the following areas. I will just list those: 4 Conventional health and safety, issues of 5 security, emergency preparedness, and fire 6 protection. 7 MR. HOWDEN: Yes, we are still 8 satisfied with the licensee's compliance in those 9 areas. 10 THE CHAIRPERSON: I would like to 11 make it clear that one of the issues that is not 12 discussed is there is a lack of scale on diagrams. 13 There is a lack of dates on photographs and, as 14 the staff knows, this is an area we have been 15 trying to emphasize. It is important in terms of 16 precision to have that kind of information in 17 order for us to have a general picture. So that 18 is a comment rather than any specific question. 19 My last question is: We noted 20 earlier some concerns on the part of the 21 Commission. There was a manager of QA, the 2.2 position was vacant. It is now filled, I believe. 23 Could both the licensee and the staff comment on 24 Is that correct, that there is a person in that? 25 that place?

StenoTran

1 MR. BENMERROUCHE: Yes, it is 2 correct. 3 MR. HOWDEN: Yes, we are aware of 4 that and they have updated their organization 5 chart to reflect this person's position, plus 6 their duties and responsibilities, and we are 7 satisfied with that. 8 THE CHAIRPERSON: My final point 9 is, I would just like to note for the record, if 10 we go back to the transcripts from the previous 11 hearing that we had in the matter, the Commission 12 had expected that there would be more progress 13 made than we have seen on the decommissioning plan 14 and the financial guarantees. 15 I would like to note that for the 16 It has been discussed quite exhaustively. record. 17 But if we look back, we had expected more progress 18 than we saw. That should be reflected in the 19 transcripts. 2.0 Mr. Graham. 21 Thank you. MEMBER GRAHAM: I have 2.2 a question on the employment and your management 23 chart. I had a note there that the Q & A person, 24 that that position was filled, but are there any 25 positions of a key nature that are not filled at

StenoTran

1 this time within the whole organization? 2 MR. THOMITNSON: The answer to 3 that is yes. The key position, long-term key 4 position of Director of Research, Mike Bancroft is 5 our Acting Director of Research. We are beginning 6 an active search for that position. Health and 7 safety, however, reports to me as Executive 8 Director, directly to me. So there is not a 9 direct line management authority there for health 10 and safety. 11 There are other positions to be 12 filled when we approach operations which will 13 involve E, S and H issues both in the operations 14 of the storage ring facility and also the 15 experimental operations on the experimental floor. 16 We will be recruiting and training the staff in 17 those areas, much as at every facility a similar 18 nature. Those will increase in number as we 19 increase our needs in terms of the number of 20 experiments. 21 Outside of those, we are also 2.2 actively looking and approaching people in the E, 23 S and H area under Dr. Benmerrouche, to continue 24 to maintain our high level of compliance there in 25 the E, S and H area, in particular, radiological

StenoTran

officer. That is active and close, we hope, to finalization.

3 So I believe that we are on target 4 with regard to the E, S and H management and 5 authority and responsibilities within our 6 organization, particularly as we are approaching 7 the transition from project to operations.

8 MEMBER GRAHAM: My question then is to CNSC staff. What check and balance or what 9 10 monitoring will you do to make sure that these 11 positions that were mentioned here this morning 12 get filled on a sliding scale or on a critical 13 path, I guess, as the project becomes a reality 14 and goes from construction into actual production? 15 What check and balance do you have on that that 16 you can monitor that or do you have a process in 17 place?

MR. HOWDEN: We do that mainly through our interaction with licensee on assessment issues and compliance issues. From our perspective at the moment, they have the staff to do the job and the staff that is qualified to do the job.

In the future, what we would be monitoring would be to know what is going on in

StenoTran

1 the health, safety, environmental area, if they 2 were losing staff, but we would be focusing on 3 their performance in terms of doses, accidents, 4 events, that type of thing, as indicators, whether 5 things were going well or not. If we saw adverse 6 trends, we would then maybe do an audit on their 7 quality assurance program to make sure that they 8 were maintaining their management oversight and 9 that their managed processes were actually being 10 used to manage health and safety.

11 MEMBER GRAHAM: Just one further 12 question. Do you have a staff member on site at 13 all times similar to a nuclear generating facility 14 or, if you don't, how often are you there to 15 monitor things like this?

16 MR. HOWDEN: We don't have any 17 staff on site. Right now we are doing inspections 18 on a frequency of twice per year. The latest 19 inspection, what we did was our staff from Ottawa 20 went, but we also are now including one of our 21 staff from our Saskatoon office, from the Uranium 2.2 Mines and Lands Evaluation Division, getting them 23 familiar with the facility such that they could go 24 in and do inspections for us or do measurements 25 for us and pass the information back to our

StenoTran

1 project officers.

2 We have just started that. Our 3 expectation is when Phase III is running that a 4 person from that office would go over and verify the radiation fields. 5 6 But the routine inspections are 7 planned right now for two times per year. 8 MR. LEBLANC: This completes the 9 record for the public hearing on the matter of an 10 application by Canadian Light Source for an 11 amendment to its particle accelerator operating 12 licence. 13 The Commission will deliberate and 14 will publish its decision in due course. It will 15 be posted on the CNSC website and will be 16 distributed to participants. 17 We will resume at 11:00 this 18 morning. When we return, we will begin with the 19 public hearing on the matter of the Environmental 20 Assessment Screening Report for the return to 21 service of Units 3 and 4 of the Bruce Nuclear 2.2 Generating Station (NGS) A. Merci. 23 THE CHAIRPERSON: Thank you very 24 much for attending today and thank you very much 25 for passing through from Saskatchewan.

StenoTran

1			MR.	WHITW	ORTH:	Thank	you	for	the
2	arra	ingements.							
3 4	MR.	BENMERROUCH	E: '	Thank	you.				

72

StenoTran